Cancer Res Treat.  2006 Apr;38(2):66-70.

The Efficacy and Safety of Padexol(R) (Paclitaxel) and Cisplatin for Treating Advanced Non-small Cell Lung Cancer

• Kim HK
• Kim JS
• Ryoo HM
• Shin DG
• Shim BY
• Park KH
• Bae SH
• Kim CH

Abstract

PURPOSE: The authors conducted a multicenter study to evaluate the efficacy and safety of combination chemotherapy with Padexol(R) and cisplatin for treating patients with advanced non-small cell lung cancer (NSCLC).
MATERIALS AND METHODS
From November 2003 to April 2005, 42 chemo-naive patients with advanced NSCLC were enrolled into this study from 4 hospitals. The treatment consisted of Padexol(R) 175 mg/m2 as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 administered as an intravenous infusion with standard premedication. The treatment was repeated every 3 weeks.
RESULTS
Among the 42 patients (pts), 33 pts were evaluable for response. On the per protocol analysis, 1 patient (pt) (3.0%) achieved complete response (CR), 17 pts (51.5%) achieved partial response (PR), 6 pts (18.2%) achieved stable disease (SD), and 9 pts (27.3%) progressed; therefore, the overall response rate was 54.6% (95% CI: 37.6~71.5%). On the intention-to-treat analysis, 1 pt (2.4%) achieved CR, 18 pts (42.9%) achieved PR, 11 pts (26.2%) achieved SD, and 9 pts (21.4%) progressed; therefore, the overall response rate was 45.2% (95% CI: 30.2~60.3%). The response, as evaluated by the investigators, was independently reviewed by 2 external radiologists and it was as follows; 13 PR (43.3%), 14 SD (46.7%) and 3 progressive disease (10%). The median duration of response was 5.9 months. The median follow-up duration was 10.3 months (range: 1.3 to 22.1 months). The median time to progression was 5.8 months (95% CI: 4.7 to 7.4 months). The median survival time on the intention-to-treat analysis was 10.5 months (95% CI: 8.1 to 18.8 months). The most common grade 3 or 4 hematologic toxicities were neutropenia (26/180 cycles, 14.4%), anemia (7/180 cycles, 3.9%) and febrile neutropenia (2/180 cycles, 1.1%). The most frequent grade 3 or 4 non-hematologic toxicities were nausea (14/42 patients, 14.3%), anorexia (3/42 patients, 7.1%) and myalgia (3/42 patients, 7.1%).
CONCLUSION
The authors observed that Padexol(R) was as good as the other paclitaxel (Taxol(R) or Genexol(R)) formulations when combined with cisplatin for treating patients with advanced NSCLC.

Keyword

Non-small cell lung cancer; Chemotherapy; Padexol(R); Cisplatin

MeSH Terms

Anemia
Anorexia
Carcinoma, Non-Small-Cell Lung*
Cisplatin*
Drug Therapy
Drug Therapy, Combination
Febrile Neutropenia
Follow-Up Studies
Humans
Infusions, Intravenous
Myalgia
Nausea
Neutropenia
Paclitaxel
Premedication
Research Personnel
Cisplatin
Paclitaxel

Figure

• 

  Fig. 1 Overall survival. The Kaplan-Meier estimate of median overall survival was 10.5 months (95% CI, 8.1 to 18.8 months).

• 

  Fig. 2 Time to disease progression. The Kaplan-Meier estimate of median time to disease progression was 5.8 months (95% CI, 4.7 to 7.4 months).

Reference

1. Jo HJ, Kim HK, Song SH, Kim CH, Cho KD, Cho DG, et al. Two Years' result of lung cancer registry in St. Vincent's Hospital. Proc Cancer Reser Treat. 2002; 34(Suppl 1):143. (#190).

2. Sandler AB, Ansari R, McClean J, Fisher W, Dorr A, Einhorn LH. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. Prog Proc Am Soc Clinc Oncol. 1995; 14:357. (abstract).

3. Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995; 13:1860–1870. PMID: 7543559.

4. von Pawel J, Wagner H, Niederle N, Heider A, Koschel G, Hecker D, et al. Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin Oncol. 1996; 23(6):Suppl 16. 47–50. PMID: 9007121.

5. Lee JA, Lee KS, Ahn JS, Byun JH, Song HH, Zang DY, et al. A phase II study of paclitaxel and cisplatin combination chemotherapy in advanced non-small cell lung cancer. Cancer Res Treat. 2003; 35:239–244.

6. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82:1247–1259. PMID: 1973737.

7. Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, et al. Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. Anticancer Drugs. 2002; 13:767–775. PMID: 12187334.

8. Chang MN, Therneau TM, Wieand HS, Cha SS. Designs for group sequential phase II clinical trilas. Biometrics. 1987; 43:865–874. PMID: 3427171.

9. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346:92–98. PMID: 11784875.

10. Kim MK, Lee KH, Hyun MS, Do YR, Song HS, Lee WS, et al. A multi-center, phase II clinical trial of Padexol® (Paclitaxel) and cisplatin for patients suffering with advanced gastric cancer. Cancer Res Treat. 20005; 37:349–353.

11. Lee SH, Park K, Suh C, Kim HK, Kim JS, Im YH, et al. A multi-center, phase II clinical trial of Genexol®(Paclitaxel) and cisplatin for patients with non-small cell lung cancer. Cancer Res Treat. 2003; 35:30–34.